Cargando…

Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease

Background: Anti-integrin therapy is a new frontline strategy in the treatment of inflammatory bowel diseases (IBD). The anti-β7 integrin antibody etrolizumab is currently being investigated for safety and efficacy in Crohn’s disease (CD) and ulcerative colitis (UC) in several phase III trials. Mech...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lichnog, Charlotte, Klabunde, Sha, Becker, Emily, Fuh, Franklin, Tripal, Philipp, Atreya, Raja, Klenske, Entcho, Erickson, Rich, Chiu, Henry, Reed, Chae, Chung, Shan, Neufert, Clemens, Atreya, Imke, McBride, Jacqueline, Neurath, Markus F., Zundler, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367223/ https://www.ncbi.nlm.nih.gov/pubmed/30774593 http://dx.doi.org/10.3389/fphar.2019.00039

Ejemplares similares

Baseline levels of dynamic CD4(+) T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study
por: Allner, Clarissa, et al.
Publicado: (2020)

Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease
por: Klenske, Entcho, et al.
Publicado: (2019)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
por: Fuchs, Friederike, et al.
Publicado: (2017)

Targeting mucosal healing in Crohn’s disease: what the clinician needs to know
por: Klenske, Entcho, et al.
Publicado: (2019)

Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo
por: Fischer, Anika, et al.
Publicado: (2016)

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
por: Mühl, Laura, et al.
Publicado: (2021)

Protective effect of the novel calcineurin inhibitor voclosporin in experimental colitis
por: Lindemann, Aylin, et al.
Publicado: (2023)

Case report of severe constrictive perimyocarditis and ischemic hepatitis in a Crohn’s disease patient upon infliximab-induced lupus-like syndrome
por: Hirschmann, Simon, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis
por: Wei, Xiaohui, et al.
Publicado: (2017)

Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
por: Becker, Emily, et al.
Publicado: (2022)

Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
por: Fischer, Sarah, et al.
Publicado: (2021)

Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti‐β7 integrin therapy for inflammatory bowel disease
por: Tang, M. T., et al.
Publicado: (2018)

Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis
por: Besendorf, Laura, et al.
Publicado: (2022)

ILC2 Lung-Homing in Cystic Fibrosis Patients: Functional Involvement of CCR6 and Impact on Respiratory Failure
por: Schulz-Kuhnt, Anja, et al.
Publicado: (2020)

α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis
por: Melde, Michaela, et al.
Publicado: (2021)

Dynamic Imaging of IEL-IEC Co-Cultures Allows for Quantification of CD103-Dependent T Cell Migration
por: Enderle, Karin, et al.
Publicado: (2021)

Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders
por: Wiesinger, Manuel, et al.
Publicado: (2017)

Comparison of Hemospray(®) and Endoclot(™) for the treatment of gastrointestinal bleeding
por: Vitali, Francesco, et al.
Publicado: (2019)

How the Tumor Micromilieu Modulates the Recruitment and Activation of Colorectal Cancer-Infiltrating Lymphocytes
por: Atreya, Imke, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
por: Zhang, Wenhui, et al.
Publicado: (2021)

Anti‐β7 integrin treatment impedes the recruitment on non‐classical monocytes to the gut and delays macrophage‐mediated intestinal wound healing
por: Sommer, Katrin, et al.
Publicado: (2023)

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
por: Zhang, Wenhui, et al.
Publicado: (2022)

Nr4a1-dependent non-classical monocytes are important for macrophage-mediated wound healing in the large intestine
por: Heidbreder, Karin, et al.
Publicado: (2023)

Deciphering Novel Mechanistic and Pharmacokinetic Effects of Tofacitinib in Intestinal Inflammation: Expect the Unexpected
por: Atreya, Raja, et al.
Publicado: (2021)

IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality
por: Atreya, Raja, et al.
Publicado: (2022)

VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer
por: Waldner, Maximilian J., et al.
Publicado: (2010)

Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers
por: Zhang, Wenhui, et al.
Publicado: (2021)

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma
por: Zundler, Sebastian, et al.
Publicado: (2023)

Endoscopic Therapy in Inflammatory Bowel Diseases
por: Neumann, Helmut, et al.
Publicado: (2015)

Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes?
por: Abdullah, Abdullah, et al.
Publicado: (2020)

Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
por: Atreya, Raja, et al.
Publicado: (2020)

Role of the IL23/IL17 Pathway in Crohn’s Disease
por: Schmitt, Heike, et al.
Publicado: (2021)

Increased Motility and Suppression of Ex Vivo–Expanded Regulatory T Cells Designed for Adoptive Transfer Therapy in Ulcerative Colitis
por: Müller, Tanja M., et al.
Publicado: (2023)

Regulation of Human Innate Lymphoid Cells in the Context of Mucosal Inflammation
por: Schulz-Kuhnt, Anja, et al.
Publicado: (2020)

Innate Lymphoid Cells as Regulators of Epithelial Integrity: Therapeutic Implications for Inflammatory Bowel Diseases
por: Schulz-Kuhnt, Anja, et al.
Publicado: (2021)

Functional Contribution and Targeted Migration of Group-2 Innate Lymphoid Cells in Inflammatory Lung Diseases: Being at the Right Place at the Right Time
por: Wirtz, Stefan, et al.
Publicado: (2021)

The outcome of patients with inflammatory bowel disease–associated colorectal cancer is not worse than that of patients with sporadic colorectal cancer–a matched-pair analysis of survival
por: Vitali, Francesco, et al.
Publicado: (2021)

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
por: Billmeier, Ulrike, et al.
Publicado: (2016)

I-scan optical enhancement for the in vivo prediction of diminutive colorectal polyp histology: Results from a prospective three-phased multicentre trial
por: Klenske, Entcho, et al.
Publicado: (2018)

Healing of the epithelial barrier in the ileum is superior to endoscopic and histologic remission for predicting major adverse outcomes in ulcerative colitis
por: Rath, Timo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c51tusc93n903ifolo8v99o2kj